Results 141 to 150 of about 1,454 (181)
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. [PDF]
Pain ManagPellesi L +5 more
europepmc +1 more source
Gepants as a New Therapeutic Option for Migraine [PDF]
Quality in SportBackground. Migraine is a common neurological disorder characterized by recurrent, often unilateral, throbbing headaches accompanied by other symptoms. It arises from sensory processing disorders involving activation of the trigeminal-vascular system and release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP), which is ...
Dominika Miazga +2 more
exaly +3 more sources
New Generation Gepants: Migraine Acute and Preventive Medications [PDF]
Journal of Clinical Medicine, 2022 Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolerability issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP)
David Moreno-Ajona +1 more
exaly +2 more sources
Gepants — A Long Way to Cure: A Narrative Review
Neurological Sciences, 2022 Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral circulation. Forty years after its discovery, the new CGRP-targeted therapy monoclonal antibodies, and the small molecule gepants, are now available for clinical practice.
Claudia Altamura +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Update of Gepants in the Treatment of Chronic Migraine
Current Pain and Headache Reports, 2023Despite the unmet therapeutic needs of patients with chronic migraine (CM) and/or medication overuse, available treatment options are limited. Recently, four calcitonin gene-related peptide receptor antagonists, known as gepants, have been approved for the treatment of migraine.
Soohyun Cho, Byung Kun Kim
exaly +3 more sources
Pharmacology; Where Do the mAbs Act, Gepants Versus mAbs
Headache, 2021 The use of monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor has recently emerged as an effective prophylactic treatment for migraine.
Alejandro Labastida-Ramírez
exaly +2 more sources
Current Pain and Headache Reports, 2023
Gepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect profile and versatility in treating headaches acutely and preventively, gepants are preferred over triptans. We will cover the indications for the four FDA-approved gepants in adults: rimegepant, atogepant, ubrogepant, and ...
Diana Li +2 more
openaire +2 more sources
Gepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect profile and versatility in treating headaches acutely and preventively, gepants are preferred over triptans. We will cover the indications for the four FDA-approved gepants in adults: rimegepant, atogepant, ubrogepant, and ...
Diana Li +2 more
openaire +2 more sources